Doxorubicin-SMCC

• Product Name Alternative:

  Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone

• UNSPSC Description:

  Doxorubicin-SMCC is a agent-linker conjugate for ADC. Doxorubicin-SMCC contains a non-cleavable ADC linker and a DNA topoisomerase II inhibitor Doxorubicin[1].

• Target Antigen:

  Drug-Linker Conjugates for ADC

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/doxorubicin-smcc.html

• Purity:

  98.80

• Solubility:

  DMSO : 62.5 mg/mL (ultrasonic)

• Smiles:

  C[C@@H]1O[C@H](C[C@@H]([C@@H]1O)NC(C2CCC(CC2)CN3C(C=CC3=O)=O)=O)O[C@H]4C[C@](O)(C(CO)=O)CC5=C(O)C(C(C6=C7C(OC)=CC=C6)=O)=C(C7=O)C(O)=C45

• Molecular Weight:

  762.76

• References & Citations:

  [1]Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  400647-59-8